MMP-Cleavable Peptide Sequences for Targeted Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to identify new substrates for proteases, specifically matrix metalloproteases (MMP), for various therapeutic, diagnostic, and prophylactic indications, as existing substrates are limited in their applications and effectiveness.
Innovation Solution
The development of specific amino acid sequences that serve as substrates for MMPs, including sequences like ISSGLLSS, QNQALRMA, and others, which can be linked to antibodies or other molecules to facilitate targeted release of therapeutic agents upon cleavage by MMPs, enabling their use in therapeutic, diagnostic, and prophylactic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing substrate sequences are used, then the basic function of MMP substrate recognition is achieved, but the therapeutic and diagnostic applications are limited
Solution Approach 1:
The cleavable moiety is divided into distinct functional segments: a MMP recognition sequence (e.g., ISSGLLSS) that ensures specific protease recognition, and a detachable linker region that can be customized for different therapeutic or diagnostic conjugates. This segmentation allows independent optimization of substrate specificity versus application versatility.
Solution Approach 2:
The patent provides a universal cleavable moiety design that can serve multiple functions: releasing therapeutic agents, delivering diagnostic probes, or enabling immunomodulatory effects. The same basic MMP recognition sequence framework can be attached to different payloads, making the substrate system multi-functional across various medical applications.
2Measurement precision
If the cleavable moiety is designed for high MMP recognition specificity, then the precision of target tissue release is improved, but the complexity of sequence design increases
Solution Approach 1:
The patent introduces an intermediary linker region between the MMP recognition sequence and the payload molecule. This intermediary element simplifies the overall design by providing a standardized interface that can accommodate different payloads while maintaining precise MMP recognition through the conserved recognition sequence, thereby reducing the complexity of custom sequence design.
Solution Approach 2:
The patent explores parameter variations in the recognition sequence (such as ISSGLLSS vs. ISSGLSS) to optimize the balance between recognition specificity and release precision. By systematically varying specific amino acid parameters within the cleavable moiety, the design achieves precise target tissue release without requiring entirely complex sequence configurations.
3Productivity
If the cleavable moiety is used to release therapeutic agents, then the efficacy of therapeutic interventions is enhanced, but the risk of off-target effects increases
Solution Approach 1:
The cleavable moiety is designed with local quality differentiation: the MMP recognition sequence provides high specificity for target tissue MMPs, while the linker and payload regions can be locally optimized to minimize off-target effects. This local quality approach ensures that therapeutic agents are released efficiently at the intended target site while reducing harmful effects at non-target locations.
Solution Approach 2:
The patent leverages the natural MMP activity in target tissues (which can be considered a 'harmful' factor in uncontrolled contexts) and converts it into a beneficial release mechanism. By designing the cleavable moiety to be specifically recognized by MMPs, the system uses the protease's natural function to trigger controlled therapeutic agent release, thereby converting potential harm into therapeutic benefit.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These MMP-substrate sequences allow for the controlled release of agents in target tissues, enhancing the efficacy of therapeutic interventions and diagnostic capabilities by leveraging the natural activity of MMPs, thereby expanding the scope of protease-based treatments and diagnostics.
Implementation Method 1
Proteases are enzymes that degrade proteins by cleaving the peptide bonds between amino acid residues. Some proteases are known to break specific peptide bonds based on the presence of a particular amino acid sequence within a protein.
Data Source
AI summary
The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.